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Cell-penetrating peptides (CPP), which are short peptides that are capable of crossing the plasma membrane of a living cell,
are under development as delivery vehicles for therapeutic agents that cannot themselves enter the cell. One well-studied CPP is
the 10-amino acid peptide derived from the human immunodeﬁciency virus type 1 (HIV-1) Tat protein. In experiments to test
the hypothesis that multiple cationic amino acids within Tat peptide confer antiviral activity against HIV-1, introduction of Tat
peptide resulted in concentration-dependent inhibition of HIV-1 IIIB infection. Using Tat peptide variants containing arginine
substitutions for two nonionic residues and two lysine residues, HIV-1 inhibition experiments demonstrated a direct relationship
between cationic charge and antiviral potency. These studies of Tat peptide as an antiviral agent raise new questions about the role
of Tat in HIV-1 replication and provide a starting point for the development of CPPs as novel HIV-1 inhibitors.
1.Introduction
Cell penetrating peptides (CPP) are short peptides that can
eﬃciently cross the plasma membrane, which is otherwise
a formidable barrier to many extracellular molecules [1–3].
CPPs are capable of not only traversing the cell membrane,
but also serving as a vehicle for transporting a variety of
cargos, including nucleic acids, polymers, nanoparticles, and
drugs that cannot otherwise gain entry to the cell [3].
AlthoughthefunctionsofvariousCPPshavebeenrepeatedly
veriﬁed in a variety of cells and conditions, the mechanism
of CPP uptake is not yet fully understood and may involve
energy-dependent and -independent mechanisms [4].
Of the numerous peptides shown to have cell penetrating
properties, a 10-amino acid (aa) peptide derived from the
human immunodeﬁciency virus type 1 (HIV-1) Tat protein
h a sb e e nw e l ls t u d i e da sa ne ﬀective CPP and an attractive
drug delivery agent [5]. The Tat peptide has received
particular emphasis as a CPP due to its simplicity and
capacityformodiﬁcationtosuitthedeliverycontextorcargo
[5, 6]. The core peptide is a 10-aa sequence comprised of six
arginine and two lysine residues, as well as two non-ionic
amino acids (Table 1). However, numerous Tat peptides of
varied lengths and terminal sequences have been investigated
with the goals of modifying activity or attaching diﬀerent
cargo [6]. A multitude of studies have determined that the
activity of the Tat peptide as a CPP involves interactions
with the cellular membrane and cytoskeleton [7], and is
inﬂuenced by numerous variables related to the peptide, the
cargo, and extracellular conditions [4].
CPPs such as the Tat peptide, the 16-aa penetratin
peptide derived from the Drosophila melanogaster Anten-
napedia homeodomain protein, and nona-arginine contain
numerous cationic arginine (R) and lysine (K) residues [2].
Interestingly, cationic charge is a feature also shared by
molecules identiﬁed as inhibitors of HIV-1 infection. Mul-
tiple cationic charges are prominent features of molecules
shown to have activity against HIV-1, including ALX40-
4C [8], NeoR6 (an aminoglycoside-arginine conjugate) [9],2 International Journal of Peptides
Table 1: Sequences of peptides examined. Peptide sequences are shown relative to the primary amino acid sequence of the Tat peptide.
Position numbers are derived from the full-length Tat protein amino acid sequence (HIV-1 strain SF2) [21].
Peptide Sequence Charge
T a t p e p t i d e GRKKRRQRRR + 8
T P v a r 1 R————————— + 9
T P v a r 2 ——————R——— + 9
T P v a r 3 R—————R——— + 1 0
R - 1 0 R—R R——R——— + 1 0
aa position 48 49 50 51 52 53 54 55 56 57
the lysozyme-derived HL9 peptide [10], the cathelicidin LL-
37 [11], the biguanide-based molecule NB325 [12–16], and
compounds that incorporate multiple guanide groups [17].
Cationic peptides found in both semen and cervicovaginal
ﬂuids were shown to eﬀectively inhibit HIV-1 infection [18,
19]. Indeed, full-length HIV-1 Tat protein, from which the
cationic Tat peptide was derived, was shown to inhibit HIV-1
infection as a CXCR4 antagonist [20].
Thepresentstudieswereconductedtotestthehypothesis
that Tat peptide, because of the numerous cationic amino
acids contained within its primary sequence, can eﬀectively
inhibit HIV-1 infection. In vitro experiments involving
Tat peptide and an HIV-1-susceptible indicator cell line
demonstrated concentration-dependent inhibition of the
X4 HIV-1 strain IIIB, which uses CXCR4 as a coreceptor.
Additional experiments involving variants of Tat peptide
with increased cationic charge suggested a direct relationship
between charge magnitude and antiviral potency. These
results provide further insights into a potential role for Tat as
an HIV-1 inhibitor and suggest a novel anti-HIV-1 activity
attributed to the family of CPPs.
2.MaterialsandMethods
2.1. Synthesis of Tat Peptide and Variants. Tat peptide
(Table 1) was derived from residues 48–57 (numbering from
HIV-1 strain SF2) of the full-length Tat protein [5, 6, 21].
Three arginine-enriched Tat peptide variants (Table 1)w e r e
designed by substituting arginine for G48, Q54, or both
amino acids. A decaarginine peptide was also included
in these studies as a Tat peptide variant with all four
nonarginine residues converted to arginines. All peptides
were synthesized commercially by liquid phase peptide
synthesis (GenScript, Pascataway, NJ) and provided at >95%
purity as determined by mass spectrometry and high-
performance liquid chromatography analysis performed by
the manufacturer (GenScript). Lyophilized peptides were
suspended in 1mL of sterile deionized water upon receipt
a n ds t o r e da t−20◦Cp r i o rt ou s e .
2.2. Cell Line Maintenance. P4-R5 MAGI indicator cells
(NIH AIDS Research and Reference Reagent Program num-
ber 3580) were maintained in Dulbecco’s modiﬁed eagle’s
media (DMEM) supplemented with 10% fetal bovine serum
(FBS), 0.05% sodium bicarbonate, antibiotics (penicillin,
streptomycin, and kanamycin at 40μg/mL), and 1μg/mL
puromycin (Cellgro, Manassas, VA).
2.3. Assessing Inhibition of HIV-1 Infection by Tat Peptide and
ItsVariants. Peptide eﬀectivenesswasdeterminedinanHIV-
1 infection inhibition assay using P4-R5 MAGI indicator
cells. P4-R5 MAGI cells were plated at a concentration
of 1.5 × 104 cells/well in a ﬂat-bottom 96-well plate (BD
Biosciences, Bedford, MA). The cells were then infected
with HIV-1 strain IIIB (Advanced Biotechnologies, Inc.,
Columbia, MD; 107.8 TCID50/mL) at multiplicities of infec-
tion (MOI) of 0.6, 0.05, or 0.03 in the presence or absence
of peptide or dextran sulfate (DS) (Sigma, St. Louis, MO).
Following a 2h incubation at 37◦C, the cells were washed
withPBS,providedwith200μLofnewmedia,andincubated
for an additional 46h. Levels of infection were measured
using the Galacto-Star-β-Galactosidase Reporter Gene Assay
System for Mammalian Cells (Applied Biosystems, Carlsbad,
CA) as described by the manufacturer. Chemiluminescence
was measured using a Glomax Luminometer plate reader
(Promega, Madison, WI).
2.4.AssessingtheEﬀectofTatPeptideonInVitroCellViability.
P4-R5 MAGI cells were plated at a concentration of 1.5 ×
104 cells/well in a ﬂat-bottom 96-well plate. The cells were
then exposed to the indicated half log concentrations of
peptide and incubated at 37◦C for 2h. Following exposure,
the cells were washed with PBS and then assayed for cell
viability immediately or at 24h or 48h after exposure.
Viability was measured using a 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay as previously
described [13].
2.5. Data Analyses. Mean values and standard deviations
were calculated from two independent assays in which each
concentration was examined in quadruplicate. Calculations
of EC50 (concentrations that resulted in 50% reductions in
infectionrelativetomock-treated,HIV-1-infectedcells)were
calculated using the Forecast function of Microsoft Excel.
3. Results
3.1. Tat Peptide Inhibits HIV-1 Infection. Initial experiments
were performed to test the hypothesis that Tat peptide, by
virtue of its cationic charge, was capable of inhibiting HIV-
1 infection. HIV-1-susceptible P4-R5 MAGI indicator cells
were exposed to HIV-1 strain IIIB (0.6 MOI) for 2h while
in the presence of half log concentrations of Tat peptide up
to 1mg/mL. The presence of Tat peptide inhibited HIV-1












































Figure 1: Tat peptide inhibits infection by HIV-1 strain IIIB. P4-
R5 MAGI cells were exposed to half log concentrations of Tat
peptide(TP)ordextransulfate(DS)inthepresenceofHIV-1strain
IIIB for 2h. Reductions in HIV-1 infection (%) were calculated
relativetomock-exposedHIV-1infected cells.Thegraphrepresents
data from two independent assays in which infections at each
concentration were repeated in quadruplicate. Error bars represent
standard deviations.
Table 2: Viral titer does not aﬀect the antiviral activity of Tat
peptide. EC50 values were calculated from the results of antiviral
assays (as described in Section 2) involving infection by HIV-1 IIIB
at three diﬀerent multiplicities of infection (MOI).
Virus concentration during infection




with an EC50 of 0.094mg/mL (50μM). No inhibition
was apparent at or below 0.0316mg/mL. At the highest
concentration tested (1mg/mL), the presence of Tat peptide
wasinsuﬃcienttocompletelyinhibitHIV-1infection(15.6%
infection relative to mock-exposed, HIV-1-infected cells). In
comparison, the anionic compound dextran sulfate, which
was included as a known inhibitor, blocked HIV-1 infection
with an EC50 of 0.0007mg/mL. To determine the potential
eﬀect of virus titer on Tat peptide antiviral activity, similar
experiments were performed using reduced concentrations
of input virus (0.05 and 0.03 MOI). In these experiments
(Table 2), reductions in input virus had no eﬀect on Tat
peptide antiviral activity (EC50 values of 0.14mg/mL and
0.10mg/mL, resp.).
To conﬁrm that any adverse eﬀects of Tat peptide on
reporter cell viability had not compromised the antiviral
assays, MTT cytotoxicity assays were performed using con-
ditions identical to those used in the antiviral assays. In
these assays, 2h exposures to Tat peptide at concentrations



























Figure 2: Tat peptide has no eﬀect on reporter cell viability. P4-
R5 MAGI cells were exposed to half log concentrations of Tat
peptide for 2h, washed, and assessed immediately for changes in
cell viability or after extended maintenance (24h or 48h after
exposure) in the absence of Tat peptide. Percent changes in cell
viability were calculated relative to mock-exposed cells. The graph
represents data from two independent assays in which exposure to
each concentration of peptide was repeated in quadruplicate. Error
bars represent standard deviations.
as measured immediately after exposure or after extended
postexposure maintenance (24h or 48h) in the absence of
Tat peptide (Figure 2). These results indicated that measure-
ments of antiviral activity were not biased by reductions in
P4-R5 MAGI cell viability. These results are also consistent
with previous studies [22], in which Tat peptide alone
(but not peptide conjugated to payload) had no eﬀect on
cell viability at concentrations up to 100μMa n de x p o s u r e
durations as long as 48h.
3.2. AdditionalCationicChargesIncreasetheAntiviral Potency
of Tat Peptide. Having demonstrated the anti-HIV-1 activity
oftheTatpeptide,additionalexperimentswereperformedto
investigatetheroleofchargeindeterminingantiviraleﬃcacy.
Of the 10 aa residues in Tat peptide, eight are cationic (six
arginine and two lysine residues) and the remaining two
are uncharged (G48, nonpolar and aliphatic; Q54, polar).
To increase the net peptide charge, arginine residues were
substituted for one or both of the noncationic residues in
thenativeTatpeptidesequence(Table 1).Thesesubstitutions
increased the net positive side chain charge of the Tat peptide
from +8 to +9 (TPvar1 and TPvar2) or +10 (TPvar3). An
additional peptide, decaarginine (R-10), was also included
in these studies. R-10 also had a net side chain charge of
+10, but diﬀered from TPvar3 in that all ten positive charges
were contributed by the arginine guanidinium groups. R-10
was, in eﬀect, a Tat peptide variant with arginine residues
substituted into all nonarginine positions. Like the Tat
peptide, none of the variants had any eﬀect on P4-R5 MAGI
















































Figure 3: Increased peptide antiviral potency is associated with
increased peptide cationic charge. P4-R5 MAGI cells were exposed
to half log concentrations of Tat peptide (TP), three Tat peptide
variants (TPvar1-3), decaarginine (R-10), or dextran sulfate (DS)
in the presence of HIV-1 strain IIIB for 2h. Peptide sequences
are depicted in Table 1. Reductions in HIV-1 infection (%) were
calculated relative to mock-exposed HIV-1 infected cells. The graph
represents data from two independent assays in which infections
at each concentration were repeated in quadruplicate. Error bars
represent standard deviations.
Concurrent incubation of HIV-1 IIIB and each peptide
with P4-R5 MAGI cells again resulted in concentration-
dependent inhibition of HIV-1 infection (Figure 3). How-
ever, the Tat peptide, the Tat peptide variants, and R-
10 diﬀered in antiviral potency, with EC50 values ranging
from 0.094mg/mL (Tat peptide) to 0.014mg/mL (R-10).
Single substitutions of arginine into the Tat peptide sequence
(G48R or Q54R) resulted in small increases in antiviral
activity relative to Tat peptide (TPvar1 EC50 = 0.065mg/mL;
TPvar2 EC50 = 0.071mg/mL). Arginine substitutions at
both positions (TPvar3) further increased peptide antiviral
activity (EC50 = 0.025mg/mL). However, despite having the
same number of positive charges, TPvar3 was less active than
R-10. No peptide was active below 0.00316mg/mL or 100%
inhibitoryatthehighestconcentrationexamined(1mg/mL).
4. Discussion
Results presented in this paper demonstrate that Tat peptide,
a CPP that is capable of delivering molecules intracellularly
[1,5]acrossliving membranes,alsocontainsintrinsic antivi-
ral activity against HIV-1 infection. Nontoxic concentrations
of Tat peptide inhibited CXCR4-mediated infection by the
X4 virus HIV-1 IIIB in a concentration-dependent manner.
In experiments designed to explore the contribution of
cationic charge to antiviral activity, Tat peptide variants
with arginine substitutions for non-ionic and lysine residues
were also assessed for antiviral activity. Increases in antiviral
potencywithincreasednetpeptidepositivechargeconﬁrmed
our original hypothesis and suggest a role for peptide charge
in the mechanism of action against HIV-1 infection.
In a broader virologic context, observations reported
herein provide new information about Tat protein and its
contributions to HIV-1-associated pathogenesis. In previous
studies, soluble full-length Tat protein, which is secreted
frominfectedcells[23],speciﬁcallyinhibitedanHIV-1strain
that used CXCR4 as a co-receptor (designated X4) but not
a CCR5-tropic (R5) strain [20]. Our preliminary results
using the Tat peptide are consistent with this observation
(data not shown). The authors speculated that, during the
course of HIV-1 infection, this mechanism attributed to
extracellular Tat could favor the replication and spread of R5
virusbyinhibitingX4virusinfection.Theyfurthersuggested
that Tat protein may interact with acidic regions of CXCR4
through the high concentration of basic residues scattered
throughout the Tat protein primary sequence [20]. However,
this study did not identify the speciﬁc sequences within
full-length Tat that were the source of the antiviral activity.
This antiviral activity was also complicated by apparent
cytotoxicity associated with exposure to extracellular full-
length Tat protein [24–27]. In contrast, the present studies
demonstrated that the Tat peptide had no adverse eﬀect on
cell viability.
These studies also provide two starting points for the
development of novel inhibitors of HIV-1. First, Tat peptide
can serve as a prototype for the development of novel agents
eﬀective against HIV-1. Such agents may take the form of
cationic peptides or small molecule inhibitors that mimic
a peptide structure. Second, Tat peptide provides the basis
for multifunctional therapeutic agents that combine the
intrinsic and speciﬁc anti-HIV-1 activity of Tat peptide with
its ability to deliver therapeutic agents that by themselves do
not readily penetrate cells and tissues [3, 6]. For example,
Tat peptide could be linked to an HIV-1 protease inhibitor to
form a dual-activity antiretroviral agent that combines entry
inhibition,increaseddrugpenetration,andasecond,distinct
mechanism of antiretroviral activity.
Our experiments also indicate that this intrinsic antiviral
activity is not limited to the Tat-derived CPP alone. In the
present studies, the R-10 peptide was also an eﬀective HIV-
1 inhibitor, despite changes in four out of ten amino acids
with respect to the Tat peptide. Preliminary studies have
also demonstrated anti-HIV-1 activity associated with the
well-studied CPP nona-arginine (R-9) and a 20-aa peptide
consisting solely of alternating arginine and glycine residues
(data not shown). The ﬁnding that antiviral activity is not
limited to Tat peptide suggests that a key characteristic
common to these molecules (i.e., multiple cationic charges)
confers activity against HIV-1.
The involvement of cationic charge in CPP antiviral
activity is also supported by the results of experiments
involving the Tat peptide variants. Those results indicated
a direct relationship between charge and antiviral activity.
Tat peptide (+8 charge) was the least active while R-10 (+10
charge) was the most active, and variants with intermediate
levels of cationic charge had intermediate levels of antiviral
activity. Despite the fact that R-10 and TPvar3 had the
same charge, these two peptides diﬀered in their eﬀectsInternational Journal of Peptides 5
on HIV-1 infection, likely due to the replacement of two
lysine residues with two arginine residues. Lysine has a
singlepositivechargeassociatedwithaterminalaminogroup
while arginine has a single positive charge associated with
a terminal guanidinium group. The charge in arginine is
delocalized across the guanidinium group, supporting the
formation of multiple hydrogen bonds [2, 28]. Polar and
charged interactions supported by the arginine end group
may favor mechanisms that are responsible for antiviral
activity and, perhaps, cell penetrating activity [5, 28].
Interestingly, peptides with multiple guanidinium groups,
such as R-10 and nona-arginine, are in the same family with
other demonstrated HIV-1 inhibitors ALX40-4C, NB325,
and LL-37, which are also cationic molecules with multiple
guanidinium groups.
Related studies have also indicated the importance of
charge in cationic HIV-1 inhibitors and provided further
evidenceforamechanismofCPPantiviralactivity.Weprevi-
ously demonstrated that charge distribution plays a key role
in the antiviral activity of biguanide-based molecules [13].
Thesemoleculesareoligomeric,cationiccompoundscharac-
terized by the presence of alternating biguanide groups and
hydrocarbon linkers [15]. Using rational compound design
and structure-function screening of biguanide-containing
synthetic molecules, studies identiﬁed polyethylene hexam-
ethylene biguanide (PEHMB; also known as NB325) as a
moleculewithminimalcytotoxicityandconsiderableactivity
against HIV-1 [12, 15]. More recent work identiﬁed NB325
as an HIV-1 entry inhibitor [14, 15] that antagonizes CXCR4
through epitope-speciﬁc interactions with extracellular loop
2 (ECL2). Further experiments demonstrated relationships
between charge density, cytotoxicity, and antiviral activity
[13]. These ﬁndings add to a collective understanding of
cationic HIV-1 inhibitors and can be used to guide further
investigations focused on deﬁning mechanisms of action and
optimizing the antiviral potency of cationic inhibitors such
as the CPPs.
These results provide the basis for further basic science
and translational studies. Expanded studies will be necessary
to investigate the antiviral eﬀect of Tat and Tat peptide
on HIV-1 replication in natively HIV-1-susceptible immune
cell populations and to better understand the contribution
of the potential bias toward R5 virus replication to viral
pathogenesis and disease progression. Related eﬀorts will
be directed toward the development of novel CPP-based
antiviral agents that can serve as multifunctional HIV-1
inhibitors. These eﬀorts will address CPP potency, stability,
mechanism of action, and combined activity as these agents
areadvancedintopreclinicalinvestigationsandclinicaltrials.
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